Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6008eac31ec519cdba832d3a8d41d30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f833ccf85c3ade6fdd54e2762647109 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6770c8e045f79538ae9b27f68fb5b85b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b59ac2e6960662f5b16de7002e604031 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 |
filingDate |
2009-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b24ad06e09ac0225d87321b4baeea157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f98a20ee77ccdb42faa8585e8ca6840 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebeaee1cdf9a54107480cb95abc6a018 |
publicationDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8710104-B2 |
titleOfInvention |
Catecholic butanes and use thereof for cancer therapy |
abstract |
The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9381246-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9834575-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015071919-A1 |
priorityDate |
2008-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |